System problems and irritations lead to nearly two in five children abandoning use of closed-loop insulin delivery in a real-world setting, researchers have reported.
Baseline data from the WISDM trial show that older adults with type 1 diabetes who have impaired awareness of hypoglycemia symptoms can spend over half an hour per day with extremely low blood glucose levels.
A 1-year exercise intervention combining high-intensity interval training with resistance training may improve measures of cardiovascular risk among people with type 2 diabetes, suggests a secondary analysis of the D2FIT trial.
Patients with type 2 diabetes and peripheral artery disease may derive greater absolute benefit from dapagliflozin than those without the comorbidity due to their increased risk for cardiovascular and renal events, DECLARE-TIMI 58 data show.
Full monitoring of biomedical and lifestyle-related diabetes target indicators is associated with significantly lower glycated hemoglobin levels than incomplete monitoring among people with type 2 diabetes in a care group setting, say researchers.
Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.
A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.
Targeting specific populations of individuals with type 2 diabetes for intensive interventions to optimize their insulin use may result in better glycemic control than an untargeted approach, findings from the TARGIT-Diabetes trial suggest.
Hypoglycemia is common among people being treated for type 2 diabetes, particularly those using insulin or a sulfonylurea, but the risk for severe episodes is only elevated among insulin users, suggest results of a prospective UK study.
Analyses of real-world audit data show positive initial results for the flash glucose monitoring system FreeStyle Libre and the sodium-glucose cotransporter 2 inhibitor canagliflozin.
A patient-specific cognitive behavioral therapy and lifestyle counseling intervention can significantly improve psychological outcomes in type 2 diabetes patients with depression and/or regimen-related distress, say researchers.
Adding an additional glucose-lowering medication is better than switching to a different one in people with type 2 diabetes, even if the original seemed to have little or no effect, shows an analysis from the MASTERMIND consortium.
Assigning people with type 2 diabetes to 3 months of focused care with a specialist diabetes nurse after an episode of severe hypoglycemia reduces their risk for mortality over the following few years, research shows.
The strongest predictors for mortality and cardiovascular disease disease in patients with type 1 diabetes are generally modifiable cardiometabolic risk factors, researchers report.
Using continuous glucose monitoring for all women with type 1 diabetes during pregnancy could save the UK National Health Service over 9 million pounds per year, report the CONCEPTT investigators.
Findings from the YOMEGA trial indicate that the one anastomosis gastric bypass procedure is noninferior to standard Roux-en-Y gastric bypass in terms of weight loss and metabolic outcomes.
Data from the TrialNet Pathway to Prevention study shows that monitoring high-risk relatives of people with type 1 diabetes markedly reduces the risk for those who develop the condition presenting with diabetic ketoacidosis.
Following the positive 2-year results of DiRECT, this symposium shared the first-hand experiences of a dietician, a general practitioner, and a person with diabetes who participated in the DiRECT study.